DrugPatentWatch - Biopharmaceutical Business Intelligence
Profile for Lifevantage Corporation (LXRX)
« Back to company indexLXRX Chatter Timeline
Stock Ticker for LXRX
Most Active Tweeters for LXRX
| User | Tweets |
|---|---|
| @gcassidy718 | 5 |
| @AmericanBanking | 4 |
| @dispatchtribune | 3 |
| @BlueBioNow | 3 |
| @ZolmaxNews | 3 |
Recent Tweets for LXRX
 |
@AmericanBanking Investment Analysts’ Weekly Ratings Changes for Lexicon Pharmaceuticals $LXRX https://t.co/1eKRitdAtd #stocks April 1st 2020, 8:04pm |
 |
@gcassidy718 $LXRX This one is getting bipolar : ) 3.99 % change recently https://t.co/GvztssB0iO March 31st 2020, 3:03pm |
 |
@BlueBioNow $LXRX buyer at $1.98 -7.69 % change recently https://t.co/e90khvbZCK March 31st 2020, 2:03am |
|
@gcassidy718 $LXRX Do we see $2.06 next? 3.89 % change recently https://t.co/GvztssB0iO March 30th 2020, 7:03pm |
 |
@dailypoliticaln Lexicon Pharmaceuticals $LXRX Stock Price Down 7.7% https://t.co/rRSah1PDiB March 29th 2020, 6:03am |
|
@BlueBioNow $LXRX major moves #LXRX -3.08 % change recently https://t.co/e90khvbZCK March 27th 2020, 8:03pm |
 |
@HealthcareBeat Lexicon Pharmaceuticals’ Buy Rating Reaffirmed at Wedbush $LXRX https://t.co/D7QRgUR8M9 March 27th 2020, 4:03am |
 |
@dakotafinancial Lexicon Pharmaceuticals’ $LXRX Buy Rating Reaffirmed at Wedbush https://t.co/KcUO12oPjP March 27th 2020, 4:03am |
 |
@stocknewstimes Lexicon Pharmaceuticals’ $LXRX Buy Rating Reaffirmed at Wedbush https://t.co/ySBoSfGT67 March 27th 2020, 4:03am |
|
@gcassidy718 $LXRX I am gona keep buying until it hits $2.06 dollars -2.09 % change https://t.co/GvztssB0iO March 26th 2020, 11:03am |
 |
@ConsumerFeed Wedbush Reaffirms Buy Rating for Lexicon Pharmaceuticals $LXRX https://t.co/1ISHB12WvY March 26th 2020, 3:03am |
 |
@ZolmaxNews Wedbush Reaffirms Buy Rating for Lexicon Pharmaceuticals $LXRX https://t.co/yNOkTQysHJ March 26th 2020, 3:03am |
 |
@TranscriptDaily Wedbush Reaffirms Buy Rating for Lexicon Pharmaceuticals $LXRX https://t.co/ruKzKLw6PD March 26th 2020, 3:03am |
|
@dailypoliticaln Wedbush Reaffirms Buy Rating for Lexicon Pharmaceuticals $LXRX https://t.co/yC0uSKWbvF March 26th 2020, 3:03am |
 |
@jomariexx @pawcio2009 $LXRX waaaay more frustrating March 25th 2020, 5:03pm |
|
@BlueBioNow $LXRX that looks like an 'I can't believe I gave you so much money and you're blowing it' kinda hand strangle -2.2… https://t.co/9NsYrUwEYE March 25th 2020, 4:03pm |
 |
@TheMarketsDaily Lexicon Pharmaceuticals $LXRX Rating Reiterated by Wedbush https://t.co/geDcPaBWqP March 25th 2020, 5:03am |
 |
@TickerReport Lexicon Pharmaceuticals $LXRX Rating Reiterated by Wedbush https://t.co/JhZYCA4Sd6 March 25th 2020, 5:03am |
 |
@dispatchtribune Lexicon Pharmaceuticals $LXRX Rating Reiterated by Wedbush https://t.co/V2K852LR7a March 25th 2020, 5:03am |
|
@AmericanBanking Lexicon Pharmaceuticals $LXRX Stock Rating Reaffirmed by Wedbush https://t.co/drWQgEbNfk #stocks March 24th 2020, 10:03pm |
 |
@SeekingAlpha $LXRX - Lexicon Pharmaceuticals Moving On From Diabetes And Pivoting Toward Clinical Candidates.… https://t.co/GWtm260f98 March 24th 2020, 5:03pm |
 |
@WatchlistN Zacks: Analysts Expect Lexicon Pharmaceuticals, Inc. $LXRX Will Announce Earnings of -$0.66 Per Share https://t.co/EZfEYr4TVV March 23rd 2020, 9:03am |
|
@dispatchtribune Lexicon Pharmaceuticals, Inc. $LXRX Expected to Announce Earnings of -$0.66 Per Share https://t.co/IsBUvyk3Fl March 23rd 2020, 9:03am |
|
@ZolmaxNews Lexicon Pharmaceuticals, Inc. $LXRX Expected to Announce Earnings of -$0.66 Per Share https://t.co/BZSurL0BVe March 23rd 2020, 9:03am |
|
@TheMarketsDaily Lexicon Pharmaceuticals, Inc. $LXRX Expected to Announce Earnings of -$0.66 Per Share https://t.co/ONQD6MK9nz March 23rd 2020, 9:03am |
|
@gcassidy718 $LXRX Never should have bought this stock . . . -14.83 % change recently https://t.co/GvztssB0iO March 23rd 2020, 5:03am |
|
@HealthcareBeat LEXICON PHARMACEUTICALS PROVIDES AN UPDATE ON THE SOTAGLIFLOZIN TYPE 2 DIABETES PROGRAM $LXRX https://t.co/RB7hM48HPh March 23rd 2020, 1:03am |
|
@HealthcareBeat Lexicon shuts down two Zynquista studies due to funding issues $LXRX https://t.co/Gj0bcLkRPH March 22nd 2020, 11:03pm |
|
@ConsumerFeed Lexicon Pharmaceuticals $LXRX Trading Down 15.9% https://t.co/62ly2FEF37 March 22nd 2020, 8:03am |
|
@TickerReport Lexicon Pharmaceuticals, Inc. $LXRX Expected to Announce Quarterly Sales of $7.07 Million https://t.co/wwCVansntt March 22nd 2020, 4:03am |
|
@AmericanBanking Lexicon Pharmaceuticals, Inc. $LXRX Expected to Announce Quarterly Sales of $7.07 Million https://t.co/p65txiLvT5 #stocks March 22nd 2020, 4:03am |
|
@stocknewstimes Lexicon Pharmaceuticals, Inc. $LXRX Receives $7.00 Average Target Price from Brokerages https://t.co/3Y59ei2PX8 March 21st 2020, 12:03pm |
|
@gcassidy718 $LXRX Looking for any entry here......... ;) 2.66 % change recently https://t.co/GvztssB0iO March 20th 2020, 8:03am |
 |
@OpenOutcrier $LXRX (-10.6% pre) LEXICON PHARMACEUTICALS PROVIDES AN UPDATE ON THE SOTAGLIFLOZIN TYPE 2 DIABETES PROGRAM https://t.co/FQvF2HuVnu March 20th 2020, 8:03am |
|
@TickerReport Zacks: Brokerages Anticipate Lexicon Pharmaceuticals, Inc. $LXRX Will Announce Earnings of -$0.66 Per Share https://t.co/BUWNjWdSGp March 20th 2020, 4:03am |
|
@AmericanBanking Zacks: Brokerages Anticipate Lexicon Pharmaceuticals, Inc. $LXRX Will Announce Earnings of -$0.66 Per Share https://t.co/q6DE52xyx3 #stocks March 20th 2020, 4:03am |
 |
@ThisLincolnian -$0.66 EPS Expected for Lexicon Pharmaceuticals, Inc. $LXRX This Quarter https://t.co/wlvA8R7fVn March 20th 2020, 4:03am |
|
@ZolmaxNews Research Analysts Set Expectations for Lexicon Pharmaceuticals, Inc.’s Q1 2021 Earnings $LXRX https://t.co/c8PQViZWCt March 20th 2020, 3:03am |
|
@dispatchtribune Lexicon Pharmaceuticals, Inc. $LXRX Forecasted to Earn Q1 2021 Earnings of -$0.35 Per Share https://t.co/fIBbMpWGBh March 20th 2020, 3:03am |
 |
@Briefingcom $LXRX: Lexicon Pharma provides update for Zynquista program in type 2 diabetes; to close out SCORED and SOLOIST... https://t.co/rTrbAzTXP0 March 19th 2020, 6:03pm |
 |
@Gambiste1 RT @MaisaCorp: $LXRX will close out early its two long-term outcomes studies of sotagliflozin, Scored and Soloist, for heart failure and ch… March 19th 2020, 5:03pm |
 |
@MaisaCorp $LXRX will close out early its two long-term outcomes studies of sotagliflozin, Scored and Soloist, for heart failu… https://t.co/XaP6Nq5sXD March 19th 2020, 5:03pm |
 |
@StckPro $LXRX NEW ARTICLE : Lexicon shuts down two Zynquista studies due to funding issues https://t.co/FDwbEnzyhD Get all… https://t.co/2Y8sEqSZIB March 19th 2020, 4:03pm |
 |
@otcdynamics $LXRX LEXICON PHARMACEUTICALS PROVIDES AN UPDATE ON THE SOTAGLIFLOZIN TYPE 2 DIABETES PROGRAM https://t.co/BLfFe3CQAu March 19th 2020, 4:03pm |
 |
@MarketCurrents $LXRX - Lexicon shuts down two Zynquista studies due to funding issues https://t.co/laoE3SQIWO March 19th 2020, 4:03pm |
 |
@Kevin_W81 $LXRX Ends ZynquistaTM (sotagliflozin) program in type 2 diabetes "near-term partnership sufficient to fund the st… https://t.co/SrlqYd9iBv March 19th 2020, 4:03pm |
 |
@BioRunUp $LXRX PROVIDES AN UPDATE ON THE SOTAGLIFLOZIN TYPE 2 DIABETES PROGRAM close out the studies early... a near-term… https://t.co/Uo9QQjFuFK March 19th 2020, 4:03pm |
 |
@odibro $LXRX UPDATE ON THE SOTAGLIFLOZIN TYPE 2 DIABETES PROGRAM. Long-Term Outcomes Studies, SCORED and SOLOIST, to Clos… https://t.co/GxWtbBzfwP March 19th 2020, 4:03pm |
|
@ZolmaxNews Lexicon Pharmaceuticals’ $LXRX Buy Rating Reaffirmed at Wedbush https://t.co/FKwUPE2255 March 19th 2020, 1:03am |
|
@TranscriptDaily Lexicon Pharmaceuticals’ $LXRX Buy Rating Reaffirmed at Wedbush https://t.co/tMKGyCypcT March 19th 2020, 1:03am |
DrugPatentWatch - Make Better Decisions
Contact © thinkBiotech LLC
2004 - 2020. All rights reserved.